These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Binocular facilitation of cone-specific visual evoked potentials in colour deficiency. Rabin J; Kryder A; Lam D Clin Exp Optom; 2018 Jan; 101(1):69-72. PubMed ID: 28636141 [TBL] [Abstract][Full Text] [Related]
43. New insights into Stargardt disease with multimodal imaging. Pang CE; Suqin Y; Sherman J; Freund KB Ophthalmic Surg Lasers Imaging Retina; 2015 Feb; 46(2):257-61. PubMed ID: 25707054 [TBL] [Abstract][Full Text] [Related]
44. Expanding the Mutation Spectrum in Nassisi M; Mohand-Saïd S; Dhaenens CM; Boyard F; Démontant V; Andrieu C; Antonio A; Condroyer C; Foussard M; Méjécase C; Eandi CM; Sahel JA; Zeitz C; Audo I Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30060493 [TBL] [Abstract][Full Text] [Related]
45. Peripapillary dark choroid ring as a helpful diagnostic sign in advanced stargardt disease. Jayasundera T; Rhoades W; Branham K; Niziol LM; Musch DC; Heckenlively JR Am J Ophthalmol; 2010 Apr; 149(4):656-660.e2. PubMed ID: 20138608 [TBL] [Abstract][Full Text] [Related]
46. Vascular abnormalities in patients with Stargardt disease assessed with optical coherence tomography angiography. Battaglia Parodi M; Cicinelli MV; Rabiolo A; Pierro L; Bolognesi G; Bandello F Br J Ophthalmol; 2017 Jun; 101(6):780-785. PubMed ID: 27628426 [TBL] [Abstract][Full Text] [Related]
47. En Face Spectral-Domain Optical Coherence Tomography for the Monitoring of Lesion Area Progression in Stargardt Disease. Melillo P; Testa F; Rossi S; Di Iorio V; Orrico A; Auricchio A; Simonelli F Invest Ophthalmol Vis Sci; 2016 Jul; 57(9):OCT247-52. PubMed ID: 27409479 [TBL] [Abstract][Full Text] [Related]
48. Foveal sparing in patients with Japanese Stargardt's disease and good visual acuity. Nakao T; Tsujikawa M; Sawa M; Gomi F; Nishida K Jpn J Ophthalmol; 2012 Nov; 56(6):584-8. PubMed ID: 22956038 [TBL] [Abstract][Full Text] [Related]
49. The Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Studies: Design and Baseline Characteristics: ProgStar Report No. 1. Strauss RW; Ho A; Muñoz B; Cideciyan AV; Sahel JA; Sunness JS; Birch DG; Bernstein PS; Michaelides M; Traboulsi EI; Zrenner E; Sadda S; Ervin AM; West S; Scholl HP; Ophthalmology; 2016 Apr; 123(4):817-28. PubMed ID: 26786511 [TBL] [Abstract][Full Text] [Related]
50. Progression of Late-Onset Stargardt Disease. Lambertus S; Lindner M; Bax NM; Mauschitz MM; Nadal J; Schmid M; Schmitz-Valckenberg S; den Hollander AI; Weber BH; Holz FG; van der Wilt GJ; Fleckenstein M; Hoyng CB; Invest Ophthalmol Vis Sci; 2016 Oct; 57(13):5186-5191. PubMed ID: 27699414 [TBL] [Abstract][Full Text] [Related]
51. Normality of colour vision in a compound heterozygous female carrying protan and deutan defects. Tait DM; Carroll J Clin Exp Optom; 2009 Jul; 92(4):356-61. PubMed ID: 19473349 [TBL] [Abstract][Full Text] [Related]
52. Quantification of peripapillary sparing and macular involvement in Stargardt disease (STGD1). Burke TR; Rhee DW; Smith RT; Tsang SH; Allikmets R; Chang S; Lazow MA; Hood DC; Greenstein VC Invest Ophthalmol Vis Sci; 2011 Oct; 52(11):8006-15. PubMed ID: 21873672 [TBL] [Abstract][Full Text] [Related]
53. Visual acuity loss and clinical observations in a large series of patients with Stargardt disease. Rotenstreich Y; Fishman GA; Anderson RJ Ophthalmology; 2003 Jun; 110(6):1151-8. PubMed ID: 12799240 [TBL] [Abstract][Full Text] [Related]